XML 39 R33.htm IDEA: XBRL DOCUMENT
v3.25.3

Organization, Basis of Presentation and Liquidity - Additional Information (Details) $ in Millions |  | 1 Months Ended | 9 Months Ended
--- | --- | --- | ---
Dec. 17, 2021 USD ($) | Aug. 31, 2025 USD ($) | Jan. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Sep. 30, 2025 USD ($) Subject Segment ClinicalTrials
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Number of clinical trials | ClinicalTrials |  |  |  |  | 2
Number of subject in Phase 1 | Subject |  |  |  |  | 5
Number of subject in Phase 1/2a | Subject |  |  |  |  | 25
Clinical development cost |  |  |  |  | $ 14.3
Additional clinical development cost |  |  |  |  | $ 7.0
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] |  |  |  |  | srt:ChiefExecutiveOfficerMember
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description |  |  |  |  | our CODM uses consolidated net loss to measure segment profit or loss, allocate resources and assess performance
Segment Reporting, Expense Information Used by CODM, Description |  |  |  |  | CODM reviews and utilizes revenue and functional expenses (cost of royalties, research and development, and general and administrative) at the consolidated level to manage our operations. Other segment items included in consolidated net loss are interest income, loss on marketable equity securities, change in fair value of warrant liability, foreign currency transaction loss, and other income (expense), and the provision for income tax benefit, which are reflected in the condensed consolidated statements of comprehensive income.
Number of operating segments | Segment |  |  |  |  | 1
Number of reportable segments | Segment |  |  |  |  | 1
Cash and cash equivalents and marketable securities |  |  |  |  | $ 40.5
Parent Company [Member] | ATM Sales Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Amount reserved for future issuance |  |  |  |  | 38.7
Maximum [Member] | Parent Company [Member] | Warrant Liabilities [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Amount reserved for future issuance |  |  |  |  | $ 35.6
Roche Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Upfront payment | $ 50.0 |  | $ 50.0 | $ 50.0 |
Maximum milestone payments to be received upon performance conditions |  |  | $ 620.0 | $ 620.0 |
Research Collaboration Agreement with William Demant Invest [Member] | Maximum [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Preclinical development research collaboration cost |  | $ 12.0 |  |  |

X
- Definition Additional clinical development cost. + References No definition available. + Details
Name: | lctx_AdditionalClinicalDevelopmentCost
Namespace Prefix: | lctx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash And Cash Equivalents And MarketableSecurities. + References No definition available. + Details
Name: | lctx_CashAndCashEquivalentsAndMarketableSecurities
Namespace Prefix: | lctx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Clinical development cost. + References No definition available. + Details
Name: | lctx_ClinicalDevelopmentCost
Namespace Prefix: | lctx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Common stock capital value reserved for future issuance. + References No definition available. + Details
Name: | lctx_CommonStockCapitalValueReservedForFutureIssuance
Namespace Prefix: | lctx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum milestone payments to be received upon performance conditions. + References No definition available. + Details
Name: | lctx_MaximumMilestonePaymentsToBeReceivedUponPerformanceConditions
Namespace Prefix: | lctx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of clinical trials. + References No definition available. + Details
Name: | lctx_NumberOfClinicalTrials
Namespace Prefix: | lctx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Subject In Phase 1 + References No definition available. + Details
Name: | lctx_NumberOfSubjectInPhase1
Namespace Prefix: | lctx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of subject in phase 12 A + References No definition available. + Details
Name: | lctx_NumberOfSubjectInPhase12A
Namespace Prefix: | lctx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Preclinical development research collaboration cost. + References No definition available. + Details
Name: | lctx_PreclinicalDevelopmentResearchCollaborationCost
Namespace Prefix: | lctx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | lctx_UpfrontPayment
Namespace Prefix: | lctx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details
Name: | us-gaap_NumberOfReportableSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 + Details
Name: | us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details
Name: | us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C + Details
Name: | us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=lctx_AtmSalesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=lctx_WarrantLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lctx_RocheAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lctx_ResearchCollaborationAgreementWithWilliamDemantInvestMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |